InterMune Inc. (ITMN) Q2 2012 Earnings Call July 23, 2012 8:30 am ET Executives Daniel Welch – President, Chief Executive Officer John Hodgman – Senior Vice President, Chief Financial Officer Giacomo Di Nepi – Managing Director, Europe Dr. Markus Leyck Dieken – Country Manager, Germany Jim Goff – Vice President, Investor Relations Analysts Michael Yee – RBC Capital Markets Brian Abrahams – Wells Fargo Ritu Baral – Canaccord Geoff Meacham – JP Morgan Brian Skorney – Brean Murray Matthew Harrison – UBS Terence Flynn – Goldman Sachs Liisa Bayko – JMP Securities Howard Liang – Leerink Swann Ravi Mehrotra – Credit Suisse Katherine Xu – William Blair Stephen Willey – Stifel Nicolaus PresentationOperator
Ladies and gentlemen, thank you for standing by and welcome to the InterMune Second Quarter 2012 Results conference call. During the presentation, all participants will be in a listen-only mode. Afterwards we will conduct a question and answer session. At that time, if you do have questions you may press the one followed by the four. If you require operator assistance at any time during the conference, you may press star, zero. As a reminder, this conference is being recorded Monday, July 23, 2012. I would now like to turn the conference over to Jim Goff, Vice President, Investor Relations. You may begin, sir. Jim Goff Thank you, Operator. Good morning and welcome to the InterMune earnings conference call. This morning we issued a press release that provides details of the Company’s unaudited financial results for the second quarter and first six months ended June 30, 2012 as well as the completion of price discussions for Esbriet in Germany. The press release is available on our website at www.intermune.com. During the course of this conference call, we will state our beliefs and make projections and other forward-looking statements regarding future events and the future financial performance of InterMune. We wish to caution you that such statements are predictions and expectations and actual events or results may differ materially. We refer you to the Company’s publicly filed SEC disclosure documents for a detailed description of the risk factors affecting our business, including those discussed in our Form 10-K filed with the SEC on February 29, 2012. These documents identify important factors that could cause our actual results to differ materially from our projections and other forward-looking statements. These risk factors include regulatory, revenue, intellectual property, clinical development, capital resources and other risks relating to our business.